Myopic maculopathy progression in highly myopic pediatric patients younger than 18 years

News
Article

A new study out of Guangzhou, China found that individuals younger than 18 years of age and experiencing high myopia are at a high risk of progressively worsening myopic maculopathy.

Child in background holding glasses with outstretched arms Image Credit: AdobeStock/Anastassiya

Image Credit: AdobeStock/Anastassiya

A research team led by first author Feng Jiang, MD, reported that myopic maculopathy progressed in about 12% of pediatric patients with high myopia over a 4-year period, with diffuse atrophy the major change. The authors called for close follow-up of these patients and identification of those at higher risk of progression.1

Jiang is affiliated with several of State Key Laboratory of Ophthalmology’s laboratories and research centers in Guangzhou, China.

The investigators emphasized that individuals with high myopia who are younger than 18 years of age are at a relatively high risk of progressively worsening myopic maculopathy. Additional studies are needed to investigate the progression of myopic maculopathy in this age group, as well as the risk factors associated with progression.

In this observational study, Jiang and colleagues investigated both the 4-year progression rate of myopic maculopathy in children and adolescents with high myopia and potential risk factors for progression.

The study included 548 high myopic eyes (spherical power −6.00 or less diopters) of 274 participants who ranged in age from 7 to 17 years. All participants underwent a comprehensive baseline ophthalmic examination and 4-year follow-up. The main outcomes were the progression of myopic maculopathy over 4 years and the associated risk factors.1

The authors reported that 67 of the 548 eyes (12.2%) had progression of myopic maculopathy over the 4-year follow-up. A total of 88 lesion changes were identified, including new signs of a tessellated fundus in 16 eyes (18.2%), diffuse atrophy in 12 eyes (13.6%), patchy atrophy in 2 eyes (2.3%), lacquer cracks in 9 eyes (10.2%), and enlargement of diffuse atrophy in 49 eyes (55.7%).

The factors identified by multivariate analysis as being associated with progression of myopic maculopathy were worse best-corrected visual acuity (odds ratio [OR], 6.68; 95% confidence interval [CI], 1.15-38.99; P = 0.04), longer axial length (OR, 1.73; 95% CI, 1.34-2.24; P < 0.001), faster axial length elongation (OR, 302.83; 95% CI, 28.61-3205.64; P < 0.001), more severe myopic maculopathy (diffuse atrophy; OR, 4.52; 95% CI, 1.98-10.30; P < 0.001 and patchy atrophy; OR, 3.82; 95% CI, 1.66-8.80; P = 0.002), according to the investigators.

Individuals under 18 years of age with high myopia are at relatively high risk of progressively worsening myopic maculopathy. Additional studies are needed to investigate the progression of myopic maculopathy in this age group and the risk factors associated with progression. These findings support consideration of follow-up in these individuals and identifying those at higher risk for progression, the authors concluded.

Reference
  1. Jiang F, Wang D, Xiao O, et al. Four-year progression of myopic maculopathy in children and adolescents with high myopia. JAMA Ophthalmol. Published online January 25, 2024. doi:10.1001/jamaophthalmol.2023.6319

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
Paul Karpecki, OD, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
© 2025 MJH Life Sciences

All rights reserved.